![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 17, 12450-12457, April 27, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(PKC
) within Structured Membrane Microdomains*From the Department of Pharmacology College of Medicine, Pennsylvania State University, Hershey, Pennsylvania 17033
We have previously demonstrated that hexanoyl-D-erythro-sphingosine (C6-ceramide), an anti-mitogenic cell-permeable lipid metabolite, limited vascular smooth muscle growth by abrogating trauma-induced Akt activity in a stretch injury model of neointimal hyperplasia. Furthermore, ceramide selectively and directly activated protein kinase C
(PKC
) to suppress Akt-dependent mitogenesis. To further analyze the interaction between ceramide and PKC
, the ability of ceramide to localize within highly structured lipid microdomains (rafts) and activate PKC
was investigated. Using rat aorta vascular smooth muscle cells (A7r5), we now demonstrate that C6-ceramide treatment results in an increased localization and phosphorylation of PKC
within caveolin-enriched lipid microdomians to inactivate Akt. In addition, ceramide specifically reduced the association of PKC
with 14-3-3, a scaffold protein localized to less structured regions within membranes. Pharmacological disruption of highly structured lipid microdomains resulted in abrogation of ceramide-activated, PKC
-dependent Akt inactivation, whereas molecular strategies suggest that ceramide-dependent PKC
phosphorylation of Akt3 at Ser34 was necessary for ceramide-induced vascular smooth muscle cell growth arrest. Taken together, these data demonstrate that structured membrane microdomains are necessary for ceramide-induced activation of PKC
and resultant diminished Akt activity, leading to vascular smooth muscle cell growth arrest.
Received for publication, January 3, 2007 , and in revised form, February 15, 2007.
* This work was supported by National Institutes of Health Grants R01HL66371 and R01HL76789 (to M. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 These authors contributed equally to this manuscript.
2 Present address: Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92673.
3 To whom correspondence should be addressed: Dept. of Pharmacology H078, Penn State College of Medicine, Hershey, PA 17033. Tel.: 717-531-8549; Fax: 717-531-5013; E-mail: mkester{at}psu.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
W. L. Holland and S. A. Summers Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocr. Rev., June 1, 2008; 29(4): 381 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Song, Z. Xie, Y. Wu, J. Xu, Y. Dong, and M.-H. Zou Protein Kinase C{zeta}-dependent LKB1 Serine 428 Phosphorylation Increases LKB1 Nucleus Export and Apoptosis in Endothelial Cells J. Biol. Chem., May 2, 2008; 283(18): 12446 - 12455. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |